Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UbeUBEOF 57 Revenue per Share is $31.95 as of Jun. 2026. GuruFocus rates UBEOF with a GF Score™ of 57/100 and a GF Value™ of $11.32. The stock has 10 warning signs investors should review. Among 1,539 Chemicals companies, Ube ranks worse than 57.05% on this metric.
Ube's revenue per share for the
three
months ended in Jun. 2026 was $7.87.
Ube's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $31.95.
Warning Sign:
Ube Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Ube was 2.50% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -2.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -5.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -3.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Ube's Revenue per Share or its related term are showing as below:
UBEOF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9 Med: -1.25 Max: 5.8
Current: -2.3
During the past 13 years, Ube's highest 3-Year average Revenue Per Share Growth Rate was 5.80% per year. The lowest was -9.00% per year. And the median was -1.25% per year.
UBEOF's 3-Year Revenue Growth Rate is ranked worse than 57.05% of 1539
companies
in the Chemicals industry
Industry Median: -0.4
vs UBEOF: -2.30
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ube Revenue per Share Related Terms
Ube Revenue per Share Historical Data
* Premium members only.
The historical data trend for Ube's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UBEOF vs LIN, SHW, ECL: Revenue per Share Comparison
For the Specialty Chemicals subindustry, Ube's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ube PS Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Ube's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ube's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Ube's Revenue Per Share for the fiscal year that ended in Mar. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ube (UBEOF) has a Revenue per Share of $31.95 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Ube and its competitors. According to the industry distribution chart, Ube ranks #878 out of 1539 companies in the Chemicals industry, placing it in the top 57.1%.
Is Ube's Revenue per Share too high?
Ube's current Revenue per Share is $31.95. Based on the distribution chart, Ube ranks #878 out of 1539 companies in the Chemicals industry, which is below the industry midpoint. Overall, Ube has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Ube's Revenue per Share compare to LIN and SHW?
According to the Chemicals industry distribution chart, Ube ranks #878 out of 1539 companies for Revenue per Share. This places Ube in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Chemicals company?
A good Revenue per Share depends on the Chemicals industry context. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Ube and its competitors. Ube's current Revenue per Share is $31.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ube stock overvalued right now?
Ube (UBEOF) has a current Revenue per Share of $31.95. The stock's GF Value™ is $11.32, compared to a current price of $15.29 — trading 35% above its estimated fair value. The current Revenue per Share is $31.95. Ube's overall GF Score™ is 57/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Ube (UBEOF), the current Revenue per Share is $31.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ube (UBEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Ube stock appears to be overvalued.
The current stock price of $15.29 is trading 35% above its estimated GF Value™ of $11.32.
Key valuation signals for UBEOF:
Revenue per Share: $31.95
GF Value™: $11.32 vs. price of $15.29 (35% above fair value)
No single metric tells the full story. See the UBEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ube Corp manufactures and sells chemicals, construction materials, and machinery products. The firm organizes itself into five segments based on product type. The chemicals segment, which generates more revenue than any other segment, sells a variety of chemicals including resins, rubber, silicon, and plastics. The cement and construction segment sells cement, plaster, and foundation materials to the construction and building industries. The pharmaceutical segment sells anti-allergic, anti-hypertensive, and anti-platelet drugs. The machinery and metal products segment sells die-casting and electric injection machines. The energy and environment segment generates electricity from coal and biomass. The majority of revenue comes from Japan.
57GF Score
Get the complete analysis for UBEOF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UBEOF has been successfully added to your 
